Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
Conditions: Organ Transplant Rejection; Psoriasis Intervention: Drug: Sustained Release Injectable Tacrolimus Sponsors: Auritec Pharmaceuticals; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Infectious Diseases | Prograf | Psoriasis | Research | Study | Tacrolimus | Transplants